Xiao Ding

发表

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Stefan Zeuzem, Norman Gitlin, M. Buti, 2014, The New England journal of medicine.

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

C. Stedman, E. Gane, E. Svarovskaia, 2013, The New England journal of medicine.

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

P. Marcellin, A. Mangia, K. Reddy, 2015, Hepatology.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

H. Mo, P. Pang, J. McHutchison, 2014, The Lancet.

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

K. Reddy, E. Gane, D. Brainard, 2015, Hepatology.

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.

H. Mo, P. Pang, K. Kowdley, 2016, Gastroenterology.

Outcomes of Treatment with Ledipasvir and Sofosbuvir Short Title : Ledipasvir / Sofosbuvir Baseline RASs and Treatment Outcomes

H. Mo, P. Pang, K. Kowdley, 2016 .

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

P. Marcellin, A. Mangia, K. Reddy, 2015, Hepatology.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

C. Stedman, P. Pang, E. Gane, 2014, Gastroenterology.

Méthodes de traitement du virus de l'hépatite c

P. Pang, R. Hyland, W. Symonds, 2014 .

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY

C. Stedman, P. Pang, E. Gane, 2013 .

Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients

M. Yuen, P. Pang, P. Tangkijvanich, 2020, Journal of Hepatology.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

H. Mo, P. Pang, J. McHutchison, 2014, The Lancet.

On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study

A. Mangia, X. Forns, G. Dore, 2016 .

Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus

K. Reddy, E. Gane, D. Brainard, 2015, Hepatology.

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

P. Marcellin, A. Mangia, K. Reddy, 2015, Hepatology.